JP Morgan Maintains Overweight on Olema Pharmaceuticals, Lowers Price Target to $46
JP Morgan analyst Anupam Rama maintains Olema Pharmaceuticals (NASDAQ:OLMA) with a Overweight and lowers the price target from $52 to $46.
Read original at benzingaStocks · News reference
Olema Pharmaceuticals Stock Falls as Pivotal Breast Cancer Data Pushed Into 2027
Olema Pharmaceuticals shares fall after completing OPERA-01 Phase 3 enrollment, with top-line data now expected in Q1 2027.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 11, 2026, 6:27 PM
- Checked
- Aug 11, 2026, 6:27 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
8-K filing — Olema Pharmaceuticals, Inc. (OLMA)
Filed: 2026-08-13 AccNo: 0001193125-26-347853 Size: 593 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Read original at edgarOlema Oncology Announces Appointment Of Jason O'Byrne As CFO
Read original at benzingaCitigroup Maintains Buy on Olema Pharmaceuticals, Lowers Price Target to $59
Citigroup analyst Yigal Nochomovitz maintains Olema Pharmaceuticals (NASDAQ:OLMA) with a Buy and lowers the price target from $62 to $59.
Read original at benzinga